Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) will host a conference call and webcast on Monday, Nov. 9, 2026, at 8:30 a.m. ET to report its third-quarter 2026 financial results and operational highlights. The announcement matters because it gives shareholders and prospective investors a scheduled checkpoint on the commercial performance of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine and the first new treatment for fibromyalgia in more than 15 years. With Tonix describing itself as a fully integrated, commercial-stage biotechnology company, the quarterly update will be the first detailed public window into how quickly TONMYA is being adopted and how the company’s central nervous system commercial infrastructure is supporting its marketed products, including the acute migraine treatments Zembrace SymTouch and Tosymra.
Beyond the near-term commercial picture, the timing of the report is significant for investors tracking Tonix’s broader strategy. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, meaning the third-quarter update could offer insight into enrollment and spending on those studies. Tonix also carries TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease, and is advancing immunology programs including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Those candidates remain investigational new drugs or biologics whose efficacy and safety have not been established and which have not been approved for any indication, so any pipeline commentary will be weighed against that regulatory reality.
Investors and interested parties can register to participate in the conference call or view the webcast through the company, and a replay will be available under “IR Events” in the Investors section of the Tonix website. For those who want the full announcement, the complete press release is available at this link. The latest news and updates relating to TNXP are also maintained in the company’s newsroom, accessible via TNXP newsroom updates, and a dedicated profile page for Tonix Pharmaceuticals (NASDAQ: TNXP) provides additional context.
The disclosure itself was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW operates within the Dynamic Brand Portfolio at IBN, a structure that delivers wire solutions through InvestorWire as well as article and editorial syndication to 5,000+ outlets. The broader reach of such distribution matters to a commercial-stage issuer like Tonix because it determines how widely a scheduled earnings date and its accompanying operational detail travel among retail and institutional audiences. Full terms of use and disclaimers applicable to all content provided by NNW are published on its site.
